18F-DCFPyL PSMA PET/CT在前列腺癌诊断准确性的2/3期前瞻性多中心研究(OSPREY)
OSPREY是一项前瞻性多中心试验,评估18F-DCFPyL PSMA PET/CT检测前列腺癌转移的诊断性能。队列A入组高危前列腺癌行根治性前列腺切除加盆腔淋巴结清扫的患者,队列B入组常规影像怀疑复发/转移的患者。结果显示队列A盆腔淋巴结特异度中位数97.9%,敏感度中位数40.3%未达预设终点;队列B前列腺外病灶敏感度中位数95.8%,阳性预测值中位数81.9%。
要点
- 队列A盆腔淋巴结特异度中位数97.9%,敏感度中位数40.3%未达预设终点。
- 队列B前列腺外病灶敏感度中位数95.8%,阳性预测值中位数81.9%。
- 两个队列高阳性预测值提示18F-DCFPyL阳性病灶很可能代表真实疾病。
核心结论
- 主要终点中特异度达标而敏感度未达标。
- 两个队列观察到的高阳性预测值提示18F-DCFPyL阳性病灶很可能代表疾病,支持其用于高危前列腺癌分期及疑似转移患者的病灶检测。
研究设计与样本
- OSPREY为前瞻性试验,共入组385例患者。
- 队列A入组252例可评估的高危前列腺癌行根治性前列腺切除加盆腔淋巴结清扫的患者。
- 队列B入组93例可评估的常规影像怀疑复发/转移的前列腺癌患者,中位PSA 11.3 ng/ml。
- 三名盲法中心读者评估18F-DCFPyL PET/CT,诊断性能基于影像结果与组织病理学比较。
主要发现
- 队列A中,三名读者对盆腔淋巴结受累的敏感度中位数40.3%(95%CI:28.1%-52.5%),特异度中位数97.9%(95%CI:94.5%-99.4%)。
- 队列A中,阳性预测值中位数86.7%(95%CI:69.7%-95.3%),阴性预测值中位数83.2%(95%CI:78.2%-88.1%)。
- 队列B中,对前列腺外病灶的敏感度中位数95.8%(95%CI:87.8%-99.0%),阳性预测值中位数81.9%(95%CI:73.7%-90.2%)。
临床怎么用
- 18F-DCFPyL PET/CT可用于高危前列腺癌患者的淋巴结或远处转移分期。
- 对于常规影像怀疑复发/转移的前列腺癌患者,18F-DCFPyL PET/CT可可靠检测疾病部位。
- 解读阳性病灶时需结合高阳性预测值,但仍需注意队列A盆腔淋巴结敏感度较低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Prostate specific membrane antigen-targeted positron emission tomography/computerized tomography has the potential to improve the detection and localization of prostate cancer. OSPREY was a prospective trial designed to determine the diagnostic performance of 18F-DCFPyL-positron emission tomography/computerized tomography for detecting sites of metastatic prostate cancer. MATERIALS AND METHODS: Two patient populations underwent 18F-DCFPyL-positron emission tomography/computerized tomography. Cohort A enrolled men with high-risk prostate cancer undergoing radical prostatectomy with pelvic lymphadenectomy. Cohort B enrolled patients with suspected recurrent/metastatic prostate cancer on conventional imaging. Three blinded central readers evaluated the 18F-DCFPyL-positron emission tomography/computerized tomography. Diagnostic performance of 18F-DCFPyL-positron emission tomography/computerized tomography was based on imaging results compared to histopathology. In cohort A, detection of pelvic nodal disease (with specificity and sensitivity as co-primary end points) and of extrapelvic metastases were evaluated. In cohort B, sensitivity and positive predictive value for prostate cancer within biopsied lesions were evaluated. RESULTS: A total of 385 patients were enrolled. In cohort A (252 evaluable patients), 18F-DCFPyL-positron emission tomography/computerized tomography had median specificity of 97.9% (95% CI: 94.5%-99.4%) and median sensitivity of 40.3% (28.1%-52.5%, not meeting prespecified end point) among 3 readers for pelvic nodal involvement; median positive predictive value and negative predictive value were 86.7% (69.7%-95.3%) and 83.2% (78.2%-88.1%), respectively. In cohort B (93 evaluable patients, median prostate specific antigen 11.3 ng/ml), median sensitivity and positive predictive value for extraprostatic lesions were 95.8% (87.8%-99.0%) and 81.9% (73.7%-90.2%), respectively. CONCLUSIONS: The primary end point for specificity was met while the primary end point for sensitivity was not. The high positive predictive value observed in both cohorts indicates that 18F-DCFPyL-positive lesions are likely to represent disease, supporting the potential utility of 18F-DCFPyL-positron emission tomography/computerized tomography to stage men with high-risk prostate cancer for nodal or distant metastases, and reliably detect sites of disease in men with suspected metastatic prostate cancer.
引用
- Pienta KJ, Gorin MA, Rowe SP, et al. A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). J Urol. 2021. PMID: 33634707. doi:10.1097/JU.0000000000001698
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。